腫瘍浸潤性リンパ球の世界市場レポート 2025年

腫瘍浸潤性リンパ球市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR14.5％で208億5,000万米ドルに成長します。予測期間の成長は、パイプラインの開発、ヘルスケア支出の増加、新興国市場、戦略的提携、規制当局の支援、患者の需要に起因します。予測期間における主な動向としては、免疫療法の進歩、研究開発イニシアティブ、規制状況、個別化医療、市場競争などが挙げられます。

がん患者の増加により、腫瘍浸潤リンパ球（TIL）市場の今後の成長が期待されます。がんは、体内の特定の細胞の制御不能な増殖を特徴とする病態であり、他の部位に転移し、様々な健康上の合併症を引き起こす可能性があり、その一部は生命を脅かす可能性があります。腫瘍浸潤リンパ球は、がん細胞を識別して排除する能力を持つ免疫細胞の一種です。このリンパ球は患者の腫瘍から抽出され、実験室で大量に培養された後、免疫系ががん細胞を攻撃するのを助けるために患者に再導入されます。例えば、2024年8月、オーストラリアの保健・福祉統計の国家機関であるオーストラリア保健福祉研究所の報告書によると、2034年までに同国では約20万9000人が新たにがんと診断される見込みで、これは2024年に予測された推定16万9000人から大幅に増加するもので、人口増加とがん罹患率の増加がもたらす影響を浮き彫りにしています。さらに、2024年には、オーストラリアでの死亡者10人のうち約3人ががんになると予測されています。したがって、がん患者の増加は腫瘍浸潤性リンパ球市場の成長を促進することになります。

個別化治療に対する患者からの需要の高まりは、腫瘍浸潤リンパ球市場の成長を当面促進する見通しです。個別化治療とは、遺伝的体質、分子形質、ライフスタイル、環境の影響など、個人の特徴に合わせて治療を調整することです。個別化治療に腫瘍浸潤リンパ球を取り入れることで、各患者のユニークな免疫プロファイルを活用し、がん治療戦略を強化することを目的としています。2023年2月、個別化医療連合（Personalized Medicine Coalition）は、2022年に米国食品医薬品局（FDA）が承認した新薬のうち、個別化治療薬が34％を占め、過去8年間の各承認の少なくとも25％に貢献したと報告しました。個別化治療に対する患者の需要の増加は、腫瘍浸潤リンパ球市場の成長を促進する主要な要因として浮上しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界腫瘍浸潤性リンパ球PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、制約）
• 最終用途産業の分析
• 世界の腫瘍浸潤性リンパ球市場：成長率分析
• 世界の腫瘍浸潤性リンパ球市場の実績：規模と成長, 2019-2024
• 世界の腫瘍浸潤性リンパ球市場の予測：規模と成長, 2024-2029, 2034F
• 世界腫瘍浸潤性リンパ球総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の腫瘍浸潤性リンパ球市場解剖学による、実績と予測, 2019-2024, 2024-2029F, 2034F
• CD3
• CD8
• CD16
• CD56
• CD4
• CD57
• CD169
• CD68
• フォックスP3
• 世界の腫瘍浸潤性リンパ球市場：コンポーネント別、実績と予測, 2019-2024, 2024-2029F, 2034F
• T細胞
• B細胞
• ナチュラルキラー細胞
• 世界の腫瘍浸潤性リンパ球市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 悪性黒色腫
• 子宮頸がん
• 卵巣がん
• その他の用途
• 世界の腫瘍浸潤性リンパ球市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• がん研究センター
• クリニック
• 世界の腫瘍浸潤性リンパ球市場、CD3のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• CD3+CD4+T細胞
• CD3+CD8+T細胞
• CD3+制御性T細胞（Treg）
• CD3+メモリーT細胞
• 世界の腫瘍浸潤性リンパ球市場、CD8のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• エフェクターCD8+T細胞
• メモリーCD8+T細胞
• 疲弊したCD8+T細胞
• 腫瘍反応性CD8+T細胞
• 世界の腫瘍浸潤性リンパ球市場、CD16のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• NK細胞（CD16+CD56dim）
• マクロファージ（CD16+マクロファージ）
• 単球（CD16+単球）
• 世界の腫瘍浸潤性リンパ球市場、CD56のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• NK細胞（CD56bright）
• NK細胞（CD56dim）
• NKT細胞
• 世界の腫瘍浸潤性リンパ球市場、CD4のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• Th1細胞
• Th2細胞
• Th17細胞
• 制御性T細胞（Treg、CD4+FOXP3+）
• 世界の腫瘍浸潤性リンパ球市場、CD57のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 老化T細胞（CD8+CD57+）
• NK細胞（CD57+NK細胞）
• CD4+CD57+T細胞
• 世界の腫瘍浸潤性リンパ球市場、CD169のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• マクロファージ（CD169+マクロファージ）
• 樹状細胞
• 世界の腫瘍浸潤性リンパ球市場、CD68のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍関連マクロファージ（TAM）
• クッパー細胞
• ミクログリア
• 世界の腫瘍浸潤性リンパ球市場FOXP3のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 制御性T細胞（Treg、CD4+CD25+FOXP3+）
• エフェクターTreg
• 休止期Treg

第7章 地域別・国別分析

• 世界の腫瘍浸潤性リンパ球市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の腫瘍浸潤性リンパ球市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 腫瘍浸潤性リンパ球市場：競合情勢
• 腫瘍浸潤性リンパ球市場：企業プロファイル
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Precision BioScience Inc. Overview, Products and Services, Strategy and Financial Analysis
  • TCR2 Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck KGaA Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Autolus Therapeutics PLC.
• Eli Lilly and Company
• Oxford Biomedica PLC.
• Unum Therapeutics Inc.
• Amgen Inc.
• Gilead Sciences Inc.
• Sorrento Therapeutics Inc.
• TILT Biotherapeutics Ltd.
• Iovance Biotherapeutics Inc.
• Adaptimmune Therapeutics plc
• Atara Biotherapeutics Inc.
• BioNTech SE
• CARsgen Therapeutics Ltd.
• Cellectis S.A.
• Celyad Oncology SA

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 腫瘍浸潤性リンパ球市場2029：新たな機会を提供する国
• 腫瘍浸潤性リンパ球市場2029：新たな機会を提供するセグメント
• 腫瘍浸潤性リンパ球市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Tumor infiltrating lymphocytes (TILs) are immune cells capable of identifying and eliminating cancer cells upon entering a tumor through the bloodstream. They are extracted from a patient's tumor, expanded in large quantities within a laboratory setting, and subsequently reintroduced into the patient's body to assist the immune system in targeting and destroying cancer cells.

Key components or anatomies of tumor-infiltrating lymphocytes encompass CD3, CD8, CD16, CD56, CD4, CD57, CD169, CD68, and FOXP3. CD3, also known as the cluster of differentiation 3, constitutes a complex protein structure involving T-cells, B-cells, and natural killer cells. These components find applications in various cancers such as melanoma, cervical cancer, ovarian cancer, among others. The end-users of these lymphocytes include hospitals, cancer research centers, and clinics involved in cancer treatment and research.

The tumor infiltrating lymphocytes market research report is one of a series of new reports from. The Business Research Company that provides tumor infiltrating lymphocytes market statistics, including tumor infiltrating lymphocytes industry global market size, regional shares, competitors with a tumor infiltrating lymphocytes market share, detailed tumor infiltrating lymphocytes market segments, market trends and opportunities, and any further data you may need to thrive in the tumor infiltrating lymphocytes industry. This tumor infiltrating lymphocytes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The tumor infiltrating lymphocytes market size has grown rapidly in recent years. It will grow from $10.6 billion in 2024 to $12.15 billion in 2025 at a compound annual growth rate (CAGR) of 14.6%. The growth in the historic period can be attributed to increasing cancer incidence, research funding, regulatory approvals, growing awareness, clinical success and efficacy.

The tumor infiltrating lymphocytes market size is expected to see rapid growth in the next few years. It will grow to $20.85 billion in 2029 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to pipeline developments, increasing healthcare expenditure, emerging markets, strategic alliances, regulatory support, patient demand. Major trends in the forecast period include advancements in immunotherapy, research and development initiatives, regulatory landscape, personalized medicine, market competition.

The increasing prevalence of cancer patients is expected to drive the growth of the tumor-infiltrating lymphocytes (TIL) market in the future. Cancer is a condition characterized by the uncontrolled growth of certain cells in the body, which can spread to other areas and cause various health complications, some of which may be life-threatening. Tumor-infiltrating lymphocytes are a type of immune cell capable of identifying and eliminating cancer cells. These lymphocytes are extracted from a patient's tumor, cultivated in large quantities in a laboratory, and then reintroduced into the patient to aid the immune system in attacking the cancer cells. For example, in August 2024, a report from the Australian Institute of Health and Welfare, a national agency for health and welfare statistics in Australia, indicated that by 2034, the country is expected to see around 209,000 new cancer diagnoses, a substantial increase from the estimated 169,000 cases projected for 2024, highlighting the effects of a growing population and increasing cancer rates. Furthermore, in 2024, cancer is predicted to account for roughly 3 out of every 10 deaths in Australia. Therefore, the rise in cancer patients is set to propel the growth of the tumor-infiltrating lymphocyte market.

The growing demand from patients for personalized therapies is poised to fuel the growth of the tumor-infiltrating lymphocyte market in the foreseeable future. Personalized therapies involve tailoring medical treatments to an individual's distinct characteristics, including genetic makeup, molecular traits, lifestyle, and environmental influences. The incorporation of tumor-infiltrating lymphocytes in customized treatments aims to enhance cancer treatment strategies by leveraging the unique immune profiles of each patient. In February 2023, the Personalized Medicine Coalition reported that personalized medications constituted 34% of new drug approvals by the US Food and Drug Administration in 2022, contributing to at least 25% of approvals in each of the preceding eight years. The increasing patient demand for personalized therapies emerges as a key driver propelling the growth of the tumor-infiltrating lymphocyte market.

Technological advancements emerge as a prominent trend gaining traction in the tumor-infiltrating lymphocytes market, with major companies strategically focusing on developing cutting-edge solutions to enhance their market positions. An illustrative example is Obsidian Therapeutics Inc., a US-based biotechnology firm specializing in engineered tumor-infiltrating lymphocytes (TIL cells) and gene treatments. In May 2022, Obsidian Therapeutics announced the introduction of cytoDRIVE technology, showcasing its ability to precisely regulate the time and level of protein activity using FDA-approved small chemicals. This technological innovation holds significant potential for treating solid cancers by employing potent cytokines such as IL12 to support cell treatments. The study revealed that various cytokines, including IL12, IL23, IL2, and IFN, could be robustly and reversibly regulated, potentially enabling their safe utilization in adoptive cell therapy applications.

Leading companies in the tumor-infiltrating lymphocyte market are pursuing a strategic partnership approach to create innovative treatments focused on gene editing. Strategic partnerships involve companies leveraging each other's strengths and resources for mutual benefit and success. For example, in February 2023, Moderna, a US-based pharmaceutical and biotechnology firm, formed a strategic collaboration with Life Edit Therapeutics, a US-based next-generation genome editing company, to expedite the development of new in vivo gene editing therapies. This partnership intends to utilize Moderna's mRNA technology in conjunction with Life Edit's proprietary genome editing platform to develop more effective and precise treatments for various conditions, including cancer and genetic disorders. This collaboration exemplifies a rising trend in the biopharmaceutical sector to integrate innovative technologies for advanced therapeutic solutions.

In May 2023, Phio Pharmaceuticals, a US-based biotechnology company, teamed up with AgonOx Inc. to enhance the development of innovative tumor-infiltrating lymphocyte (TIL) therapies for cancer patients. This partnership aims to leverage Phio's proprietary technology in engineered TILs alongside AgonOx's expertise in immuno-oncology, potentially leading to improved treatment options for patients with solid tumors. AgonOx Inc. is a US-based company focused on developing novel therapies for cancer patients.

Major companies operating in the tumor infiltrating lymphocytes market include Novartis AG, Pfizer Inc., Precision BioScience Inc., TCR2 Therapeutics Inc., Merck KGaA, Autolus Therapeutics PLC., Eli Lilly and Company, Oxford Biomedica PLC., Unum Therapeutics Inc., Amgen Inc., Gilead Sciences Inc., Sorrento Therapeutics Inc., TILT Biotherapeutics Ltd., Iovance Biotherapeutics Inc., Adaptimmune Therapeutics plc, Atara Biotherapeutics Inc., BioNTech SE, CARsgen Therapeutics Ltd., Cellectis S.A., Celyad Oncology SA, CRISPR Therapeutics AG, Intellia Therapeutics Inc., MaxCyte Inc.

North America was the largest region in the tumor infiltrating lymphocytes market in 2024. The regions covered in the tumor infiltrating lymphocytes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the tumor infiltrating lymphocytes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The tumor infiltrating lymphocytes market consists of sales of autologous TILs (tumor infiltrating lymphocytes), allogeneic TILs, and engineered TILs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Tumor Infiltrating Lymphocytes Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on tumor infiltrating lymphocytes market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for tumor infiltrating lymphocytes ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The tumor infiltrating lymphocytes market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Anatomy: CD3; CD8; CD16; CD56; CD4; CD57; CD169; CD68; FOXP3
• 2) By Component: T-Cells; B-Cells; Natural Killer Cells
• 3) By Application: Melanoma; Cervical Cancer; Ovarian Cancer; Other Applications
• 4) By End-User: Hospitals; Cancer Research Centers; Clinics
• Subsegments:
• 1) By CD3: T-Cell Activation Markers
• 2) By CD8: Cytotoxic T Cells
• 3) By CD16: Natural Killer (NK) Cells
• 4) By CD56: NK Cell Markers
• 5) By CD4: Helper T Cells
• 6) By CD57: Senescent T Cells
• 7) By CD169: Macrophage Activation
• 8) By CD68: Macrophage Markers
• 9) By FOXP3: Regulatory T Cells (Tregs)
• Companies Mentioned: Novartis AG; Pfizer Inc.; Precision BioScience Inc.; TCR2 Therapeutics Inc.; Merck KGaA
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Tumor Infiltrating Lymphocytes Market Characteristics

3. Tumor Infiltrating Lymphocytes Market Trends And Strategies

4. Tumor Infiltrating Lymphocytes Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Tumor Infiltrating Lymphocytes Growth Analysis And Strategic Analysis Framework

• 5.1. Global Tumor Infiltrating Lymphocytes PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Tumor Infiltrating Lymphocytes Market Growth Rate Analysis
• 5.4. Global Tumor Infiltrating Lymphocytes Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Tumor Infiltrating Lymphocytes Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Tumor Infiltrating Lymphocytes Total Addressable Market (TAM)

6. Tumor Infiltrating Lymphocytes Market Segmentation

• 6.1. Global Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• CD3
• CD8
• CD16
• CD56
• CD4
• CD57
• CD169
• CD68
• FOXP3
• 6.2. Global Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• T-Cells
• B-Cells
• Natural Killer Cells
• 6.3. Global Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Melanoma
• Cervical Cancer
• Ovarian Cancer
• Other Applications
• 6.4. Global Tumor Infiltrating Lymphocytes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Cancer Research Centers
• Clinics
• 6.5. Global Tumor Infiltrating Lymphocytes Market, Sub-Segmentation Of CD3, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• CD3+ CD4+ T cells
• CD3+ CD8+ T cells
• CD3+ T regulatory cells (Tregs)
• CD3+ Memory T cells
• 6.6. Global Tumor Infiltrating Lymphocytes Market, Sub-Segmentation Of CD8, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Effector CD8+ T cells
• Memory CD8+ T cells
• Exhausted CD8+ T cells
• Tumor-reactive CD8+ T cells
• 6.7. Global Tumor Infiltrating Lymphocytes Market, Sub-Segmentation Of CD16, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• NK Cells (CD16+ CD56dim)
• Macrophages (CD16+ macrophages)
• Monocytes (CD16+ monocytes)
• 6.8. Global Tumor Infiltrating Lymphocytes Market, Sub-Segmentation Of CD56, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• NK Cells (CD56bright)
• NK Cells (CD56dim)
• NKT Cells
• 6.9. Global Tumor Infiltrating Lymphocytes Market, Sub-Segmentation Of CD4, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Th1 Cells
• Th2 Cells
• Th17 Cells
• T Regulatory Cells (Tregs, CD4+ FOXP3+)
• 6.10. Global Tumor Infiltrating Lymphocytes Market, Sub-Segmentation Of CD57, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Senescent T cells (CD8+ CD57+)
• NK Cells (CD57+ NK cells)
• CD4+ CD57+ T cells
• 6.11. Global Tumor Infiltrating Lymphocytes Market, Sub-Segmentation Of CD169, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Macrophages (CD169+ macrophages)
• Dendritic Cells
• 6.12. Global Tumor Infiltrating Lymphocytes Market, Sub-Segmentation Of CD68, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tumor-Associated Macrophages (TAMs)
• Kupffer Cells
• Microglia
• 6.13. Global Tumor Infiltrating Lymphocytes Market, Sub-Segmentation Of FOXP3, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• T Regulatory Cells (Tregs, CD4+ CD25+ FOXP3+)
• Effector Tregs
• Resting Tregs

7. Tumor Infiltrating Lymphocytes Market Regional And Country Analysis

• 7.1. Global Tumor Infiltrating Lymphocytes Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Tumor Infiltrating Lymphocytes Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Tumor Infiltrating Lymphocytes Market

• 8.1. Asia-Pacific Tumor Infiltrating Lymphocytes Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Tumor Infiltrating Lymphocytes Market

• 9.1. China Tumor Infiltrating Lymphocytes Market Overview
• 9.2. China Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Tumor Infiltrating Lymphocytes Market

• 10.1. India Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Tumor Infiltrating Lymphocytes Market

• 11.1. Japan Tumor Infiltrating Lymphocytes Market Overview
• 11.2. Japan Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Tumor Infiltrating Lymphocytes Market

• 12.1. Australia Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Tumor Infiltrating Lymphocytes Market

• 13.1. Indonesia Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Tumor Infiltrating Lymphocytes Market

• 14.1. South Korea Tumor Infiltrating Lymphocytes Market Overview
• 14.2. South Korea Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Tumor Infiltrating Lymphocytes Market

• 15.1. Western Europe Tumor Infiltrating Lymphocytes Market Overview
• 15.2. Western Europe Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Tumor Infiltrating Lymphocytes Market

• 16.1. UK Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Tumor Infiltrating Lymphocytes Market

• 17.1. Germany Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Tumor Infiltrating Lymphocytes Market

• 18.1. France Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Tumor Infiltrating Lymphocytes Market

• 19.1. Italy Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Tumor Infiltrating Lymphocytes Market

• 20.1. Spain Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Tumor Infiltrating Lymphocytes Market

• 21.1. Eastern Europe Tumor Infiltrating Lymphocytes Market Overview
• 21.2. Eastern Europe Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Tumor Infiltrating Lymphocytes Market

• 22.1. Russia Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Tumor Infiltrating Lymphocytes Market

• 23.1. North America Tumor Infiltrating Lymphocytes Market Overview
• 23.2. North America Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Tumor Infiltrating Lymphocytes Market

• 24.1. USA Tumor Infiltrating Lymphocytes Market Overview
• 24.2. USA Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Tumor Infiltrating Lymphocytes Market

• 25.1. Canada Tumor Infiltrating Lymphocytes Market Overview
• 25.2. Canada Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Tumor Infiltrating Lymphocytes Market

• 26.1. South America Tumor Infiltrating Lymphocytes Market Overview
• 26.2. South America Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Tumor Infiltrating Lymphocytes Market

• 27.1. Brazil Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Tumor Infiltrating Lymphocytes Market

• 28.1. Middle East Tumor Infiltrating Lymphocytes Market Overview
• 28.2. Middle East Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Tumor Infiltrating Lymphocytes Market

• 29.1. Africa Tumor Infiltrating Lymphocytes Market Overview
• 29.2. Africa Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Tumor Infiltrating Lymphocytes Market Competitive Landscape And Company Profiles

• 30.1. Tumor Infiltrating Lymphocytes Market Competitive Landscape
• 30.2. Tumor Infiltrating Lymphocytes Market Company Profiles
  • 30.2.1. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Precision BioScience Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. TCR2 Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis

31. Tumor Infiltrating Lymphocytes Market Other Major And Innovative Companies

• 31.1. Autolus Therapeutics PLC.
• 31.2. Eli Lilly and Company
• 31.3. Oxford Biomedica PLC.
• 31.4. Unum Therapeutics Inc.
• 31.5. Amgen Inc.
• 31.6. Gilead Sciences Inc.
• 31.7. Sorrento Therapeutics Inc.
• 31.8. TILT Biotherapeutics Ltd.
• 31.9. Iovance Biotherapeutics Inc.
• 31.10. Adaptimmune Therapeutics plc
• 31.11. Atara Biotherapeutics Inc.
• 31.12. BioNTech SE
• 31.13. CARsgen Therapeutics Ltd.
• 31.14. Cellectis S.A.
• 31.15. Celyad Oncology SA

32. Global Tumor Infiltrating Lymphocytes Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Tumor Infiltrating Lymphocytes Market

34. Recent Developments In The Tumor Infiltrating Lymphocytes Market

35. Tumor Infiltrating Lymphocytes Market High Potential Countries, Segments and Strategies

• 35.1 Tumor Infiltrating Lymphocytes Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Tumor Infiltrating Lymphocytes Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Tumor Infiltrating Lymphocytes Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer